Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study

BACKGROUND: The relationship between use of proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H(2)RAs) and pancreatic cancer risk has yet to be examined. Data from a range of studies suggest biologically plausible mechanisms, whereby these drugs (or the conditions for which they ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, M C, Murray, L J, Cantwell, M M, Hughes, C M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251858/
https://www.ncbi.nlm.nih.gov/pubmed/22108522
http://dx.doi.org/10.1038/bjc.2011.511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251858/
https://www.ncbi.nlm.nih.gov/pubmed/22108522
http://dx.doi.org/10.1038/bjc.2011.511

Ejemplares similares